ClinicalTrials.gg
CompletedNCT03969212Updated Jul 4, 2025Results posted

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

A Phase 3 interventional study of Baloxavir Marboxil and Placebo in Influenza, sponsored by Hoffmann-La Roche. Completed at 142 sites in 16 countries. Open to participants aged 5 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
4,138
Allocation
Randomized
Ages
5 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
2nd of 18
4,138 · median 483
Started
2019
with 3 others
Phase 3
12 of 18
5 open now
Registered
7th of 18
by date
Lead sponsor
7 of 18
Hoffmann-La Roche

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 2nd largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 7th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 5 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

Otherwise healthy index patients (IP) are randomized to either baloxavir marboxil or placebo if their influenza symptoms onset was within 48 hours of screening. Their households are enrolled within 24 hours of randomization if at least 1 household contacts (HHC) have not received influenza vaccine within 6 months of screening and if all HHC screen negative for influenza infection. The main endpoints are assessed based on multiple respiratory swabs, obtained from both IP and HHC up to 9 (+/-1) days post IP randomization, and through the assessment of symptoms.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
5 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Index Patients (IPs):

  • Able to comply with the study protocol per investigator judgment.
  • Diagnosed with acute influenza infection by investigator.
  • Polymerase chain reaction [PCR] (+) or Rapid Influenza Diagnostic Test [RIDT] (+) for influenza A/B based on cobas® SARS-CoV-2 and influenza A/B or other point-of-care / local laboratory results.
  • PCR (-) or antigen test (-) for SARS-CoV-2 based on cobas® SARS-CoV-2 and Influenza A/B test or other point-of-care / local laboratory result
  • Presence of (a) fever (>=38.0 °C per tympanic or rectal thermometer; >=37.5 °C per axillary, oral or forehead/temporal thermometer) or (b) any influenza symptoms (cough, sore throat, nasal congestion, headache, feverishness or chills, muscle or joint pain, fatigue).
  • The time interval between the onset of fever or influenza symptoms and the pre-dose examinations is 48 hours or less.
  • IP lives in a household where: (1) No HHC is known to have been diagnosed with influenza or SARS-CoV-2 infection by a healthcare professional (HCP) in the past 4 weeks; (2) All HHCs are expected to meet the key HHC inclusion criteria; (3) >=1 HHCs are expected to participate in the full study who have not received the influenza vaccine within 6 months prior to screening.
  • Women of : Agreement to remain abstinent (refrain from heterosexual intercourse) or use measures specified in the protocol

All HHCs (Part 1):

  • PCR (-) or RIDT (-) based on cobas® SARS-CoV-2 and influenza A/B or other local point-of-care / local laboratory result.
  • PCR (-) or antigen test (-) for SARS-CoV-2 based on cobas® SARS-CoV-2 and Influenza A/B or other POC / local laboratory result.
  • HHC lives with no HHC who will be present in the home at any time during the study and who meets any HHC exclusion criteria.
  • HHC lives with no HHC who does not meet HHC inclusion criteria (part 1).
  • HHC lives in a household where ≥1 HHCs meet all of the following: Start screening within 24 hours after IP randomization; Have NOT received the influenza vaccine within 6 months prior to screening; and Fulfill full study HHC inclusion criteria part 2.

Full study HHCs (part 2) intended for full study must meet the following additional criteria for study entry:

  • Agree to participate in the full study.
  • Able to comply with the study protocol per investigator judgment
  • No influenza symptoms within 7 days prior to screening. Alternatively, mild symptoms are permissible if determined by the investigator to be due to a preexisting condition.
  • Temperature \<38.0 °C (tympanic).
  • Will reside in the index patient's house for at least 7 of the next 9 days and will be present for scheduled study visits.
  • Willing and able to measure and record temperature, or have another household member perform the task on his or her behalf. Furthermore, a responsible adult will assume responsibility to oversee or perform this task on behalf of minors.
  • In the 6 months prior to screening: a) Has not been diagnosed with influenza by a healthcare professional b) Has not received BXM, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, favipiravir or amantadine.
  • Does not have a moderate or worse active infections OR infections requiring systemic (e.g., oral or intravenous) or otherwise internally administered (e.g., inhaled, intrathecal) antibiotic/antiviral/antifungal therapy, (topical therapies for mild external infections allowed).

Exclusion criteria

EXCLUSION CRITERIA:

IPs:

  • IPs with severe influenza virus infection requiring inpatient treatment.
  • IPs judged by the investigator to be at high risk for complications of influenza.
  • IP is ≥12 years old and unable to swallow tablets (not applicable to IPs 5 to 11 year olds who will receive oral suspension).
  • Women who are breastfeeding or have a positive pregnancy test in the pre-dose examinations.
  • IPs with concurrent (non-influenza) infections requiring systemic antimicrobial and/or antiviral therapy at the pre-dose examinations.
  • IPs who have received baloxavir marboxil, peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir, favipiravir or amantadine, or an drug, within 30 days or 5 drug-elimination half-lives, whichever is longer, prior to screening.
  • IPs who have received an investigational monoclonal antibody for a viral disease in the last year.
  • Known to baloxavir marboxil or the drug product .
  • IP previously included in the study
  • IP lives with an HHC who, based on available information, meets the HHC exclusion criteria

HHC:

  • Pregnant or within 2 weeks post-partum at screening.
  • .
  • Less than 2 years old.
  • Who have received an investigational therapy within the 30 days or 5 drug elimination half-lives, whichever is longer, prior to screening.
  • Diagnosed with influenza or SARS-CoV-2 infection by a healthcare professional in the past 4 weeks.
  • HHC who plans to arrive home after 24 hours post IP randomization to Day 9 and is not willing to be consented as soon as possible upon arrival.
  • HHC previously included in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
4,138 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil

    Participants who are IPs will receive a single oral dose of baloxavir marboxil. HHCs of the IPs will not receive study medication.

    Drug: Baloxavir Marboxil

  • Placebo comparator
    Placebo

    Participants who are IPs will receive a single oral dose of placebo. HHCs of the IPs will not receive study medication.

    Drug: Placebo

Interventions

  • IPs less than 12 years old will receive either 2 mg/kg (if weight less than 20 kg) or 40 mg (if weight more than or equal to 20 kg) of Baloxavir Marboxil as oral suspension. IPs more than or equal to 12 years old will receive either 40 mg (if weight less than 80 kg) or 80 mg (if weight more than or equal to 80 kg) of Baloxavir Marboxil as tablets. HHCs of IPs will not receive study medication.

    Also known as: Xofluza

  • DrugPlacebo

    IPs less than 12 years old will receive placebo oral suspension and those above 12 years will receive placebo tablets. HHCs of IPs will not receive study medication.

06

What researchers measure

Primary outcomes

  1. Percentage of HHCs With Virological Influenza Transmission by Day 5

    The virological transmission was determined based on Polymerase Chain Reaction Positive (PCR+) influenza test results. The adjusted incidence (cumulative proportion of events by Day 5) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 5 post IP randomization with virus subtype matching with that of the respective IP, irrespective of being symptomatic or asymptomatic. The adjusted incidence rates presented were estimated using a generalized estimating equations (GEE) approach.

    Time frame: Baseline (Day 1) to Day 5

Secondary outcomes

  1. Percentage of HHCs With Symptomatic Influenza Transmission by Day 5

    The adjusted incidence (cumulative proportion of events by Day 5) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 5 post IP randomization with virus subtype matching with that of respective IP, \& developed symptoms at any time during the study. The adjusted incidence rates presented were estimated using a GEE approach. HHCs ≥12 years old were symptomatic if 1. Presence of temperature ≥38.0 Celsius (C) and 1 respiratory symptom (cough, sore throat, nasal congestion) or 2. Presence of 1 respiratory symptom and 1 general systemic symptom (headache, feverishness or chills, muscle or joint pain, fatigue), with/without a fever. HHCs ≥2 and \<12 years old were symptomatic if the presence of temperature was ≥38.0°C and had upper respiratory tract infection signs or symptoms (cough, nasal congestion, or rhinorrhea). Symptoms must be either new or have worsened versus baseline in HHC with baseline symptoms due to a preexisting comorbidity.

    Time frame: Baseline (Day 1) to Day 5

  2. Percentage of Households (HHs) With Virological Influenza Transmission at Household Level by Day 5

    Percentage of households with at least one HHC who met the primary endpoint of virological transmission by Day 5 are reported here. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

    Time frame: Baseline (Day 1) to Day 5

  3. Percentage of HHs With Symptomatic Influenza Transmission at Household Level by Day 5

    Percentage of HHs with at least one HHC who meets the symptomatic transmission by Day 5 endpoint are reported here. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

    Time frame: Baseline (Day 1) to Day 5

  4. Percentage of HHCs With Virological Influenza Transmission by Day 9

    The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 9 post IP randomization with virus subtype matching with the respective IP, irrespective of being symptomatic or asymptomatic including: 1. all HHC meeting primary endpoint, AND 2. all HHC cases detected after Day 5 meeting the following criteria: 2a. included HHC case was in an HH where another HHC had already met the primary endpoint OR 2b. included HHC case was PCR+ bearing an amino acid substitution of isoleucine for another amino acid at position 38 (I38X) in the polymerase acidic (PA) protein (PA/I38X substitution) or amino acid substitution of threonine to lysine at position 20 in the PA protein for influenza B only (PA/T20K). The adjusted incidence rates presented were estimated using a GEE approach.

    Time frame: Baseline (Day 1) to Day 9

  5. Percentage of HHCs With Symptomatic Influenza Transmission by Day 9

    The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who met the virological transmission by Day 9 endpoint and developed symptoms at any time during the study. The adjusted incidence rates presented were estimated using a GEE approach. HHCs ≥12 years were symptomatic if they had 1. temperature ≥38.0°C and one respiratory symptom (cough, sore throat, nasal congestion) or 2. one respiratory and one general systemic symptom (headache, feverishness or chills, muscle or joint pain, fatigue), with or without fever. HHCs ≥2 and \<12 years were symptomatic if the presence of temperature was ≥38.0°C and had upper respiratory symptoms (headache, feverishness or chills, muscle or joint pain, fatigue). Symptoms must be either new or have worsened versus baseline in HHC with baseline symptoms due to a preexisting comorbidity.

    Time frame: Baseline (Day 1) to Day 9

  6. Percentage of HHCs With Any Virological Infection by Day 9

    Virological infection was defined as HHCs who tested PCR+ for influenza by Day 9 post IP randomization based on PCR influenza test results. The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who met the virological infection by Day 9 endpoint. The adjusted incidence rates presented were estimated using a GEE approach.

    Time frame: Baseline (Day 1) to Day 9

  7. Percentage of HHs With Any Virological Infection at HH Level by Day 9

    Virological infection at the HH level was defined as the HHs with at least one HHC who met the endpoint of any virological infection by Day 9. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

    Time frame: Baseline (Day 1) to Day 9

  8. Percentage of HHCs With Any Symptomatic Infection by Day 9

    The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 9 post IP randomization and developed symptoms at any time during the study. The adjusted incidence rates presented were estimated using a GEE approach. HHCs ≥12 years were symptomatic if they had (1) a temperature ≥38.0°C and one respiratory symptom (cough, sore throat, nasal congestion) or (2) one respiratory and one systemic symptom (headache, chills, muscle/joint pain, fatigue), with or without fever. HHCs ≥2 and \<12 years were symptomatic if the presence of temperature was ≥38.0°C and had upper respiratory symptoms (cough, nasal congestion, rhinorrhea). Symptoms must be either new or have worsened versus baseline in HHC with baseline symptoms due to a preexisting comorbidity.

    Time frame: Baseline (Day 1) to Day 9

  9. Percentage of HHs With Any Symptomatic Infection at HH Level by Day 9

    Percentage of HHs with at least one HHC who meets the endpoint of any symptomatic infection by Day 9 are reported here. HHCs ≥12 years were symptomatic if they had 1. a temperature ≥38.0°C \&1 respiratory symptom (cough, sore throat, nasal congestion) or 2. 1 respiratory \& 1 systemic symptom (headache, chills, muscle/joint pain, fatigue), with/without fever. HHCs ≥2 \& \<12 years were symptomatic if the temperature was ≥38.0°C \& had upper respiratory symptoms (cough, nasal congestion, rhinorrhea). Symptoms must be new or have worsened versus baseline in HHC with baseline symptoms due to preexisting comorbidity. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

    Time frame: Baseline (Day 1) to Day 9

  10. Number of IPs With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

    Time frame: Baseline up to Day 9 (for IPs ≥12 years old) and Day 21 (for IPs <12 years old)

  11. Number of IPs With Serious Adverse Events (SAEs)

    A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

    Time frame: Baseline up to Day 9 (for IPs ≥12 years old) and Day 21 (for IPs <12 years old)

07

Results

Posted Apr 24, 2025

Participant flow

Participants with acute influenza infection (Index participants \[IPs\]) and their household contacts (HHCs) took part in the study across 142 investigative sites in 15 countries from 10 October 2019 to 10 May 2024. A total of 4138 participants, 1457 IPs, and 2681 HHCs, were included in the study.

Participant flow — Overall Study
MilestonePlacebo: IPsBaloxavir Marboxil: IPsPlacebo: HHCsBaloxavir Marboxil: HHCs
Started73172613361345
Treated72672300
Completed69968813001305
Not completed32383640
Withdrew: Adverse event1000
Withdrew: Lost to follow-up2222
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject713511
Withdrew: Physician decision0010
Withdrew: Reason not specified22232826

Outcome measures

PrimaryPercentage of HHCs With Virological Influenza Transmission by Day 5

The virological transmission was determined based on Polymerase Chain Reaction Positive (PCR+) influenza test results. The adjusted incidence (cumulative proportion of events by Day 5) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 5 post IP randomization with virus subtype matching with that of the respective IP, irrespective of being symptomatic or asymptomatic. The adjusted incidence rates presented were estimated using a generalized estimating equations (GEE) approach.

Time frame:
Baseline (Day 1) to Day 5
Reported as:
Number · percentage of HHCs
Percentage of HHCs With Virological Influenza Transmission by Day 5
percentage of HHCsPlacebo: HHCsBaloxavir Marboxil: HHCs
Percentage of HHCs With Virological Influenza Transmission by Day 513.42 (10.66 to 16.76)9.50 (7.40 to 12.13)
Statistical analysis
  • Placebo: HHCs vs Baloxavir Marboxil: HHCs · GEE · p = = 0.013 · Adjusted or (bmx vs placebo): 0.68 · 95.38% CI 0.50 to 0.93
SecondaryPercentage of HHCs With Symptomatic Influenza Transmission by Day 5

The adjusted incidence (cumulative proportion of events by Day 5) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 5 post IP randomization with virus subtype matching with that of respective IP, \& developed symptoms at any time during the study. The adjusted incidence rates presented were estimated using a GEE approach. HHCs ≥12 years old were symptomatic if 1. Presence of temperature ≥38.0 Celsius (C) and 1 respiratory symptom (cough, sore throat, nasal congestion) or 2. Presence of 1 respiratory symptom and 1 general systemic symptom (headache, feverishness or chills, muscle or joint pain, fatigue), with/without a fever. HHCs ≥2 and \<12 years old were symptomatic if the presence of temperature was ≥38.0°C and had upper respiratory tract infection signs or symptoms (cough, nasal congestion, or rhinorrhea). Symptoms must be either new or have worsened versus baseline in HHC with baseline symptoms due to a preexisting comorbidity.

Time frame:
Baseline (Day 1) to Day 5
Reported as:
Number · percentage of HHCs
Percentage of HHCs With Symptomatic Influenza Transmission by Day 5
percentage of HHCsPlacebo: HHCsBaloxavir Marboxil: HHCs
Percentage of HHCs With Symptomatic Influenza Transmission by Day 57.61 ± 5.665.80 ± 4.10
Statistical analysis
  • Placebo: HHCs vs Baloxavir Marboxil: HHCs · GEE model · p = = 0.1550 · Adjusted or (bmx vs placebo): 0.75 · 95.38% CI 0.50 to 1.12
SecondaryPercentage of Households (HHs) With Virological Influenza Transmission at Household Level by Day 5

Percentage of households with at least one HHC who met the primary endpoint of virological transmission by Day 5 are reported here. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

Time frame:
Baseline (Day 1) to Day 5
Reported as:
Number · percentage of HHs
Percentage of Households (HHs) With Virological Influenza Transmission at Household Level by Day 5
percentage of HHsPlacebo: IPsBaloxavir Marboxil: IPs
Percentage of Households (HHs) With Virological Influenza Transmission at Household Level by Day 519.515.5
Statistical analysis
  • Placebo: IPs vs Baloxavir Marboxil: IPs · Odds ratio (bmx vs placebo}]: 0.76 · 95.38% CI 0.55 to 1.06
SecondaryPercentage of HHs With Symptomatic Influenza Transmission at Household Level by Day 5

Percentage of HHs with at least one HHC who meets the symptomatic transmission by Day 5 endpoint are reported here. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

Time frame:
Baseline (Day 1) to Day 5
Reported as:
Number · percentage of HHs
Percentage of HHs With Symptomatic Influenza Transmission at Household Level by Day 5
percentage of HHsPlacebo: IPsBaloxavir Marboxil: IPs
Percentage of HHs With Symptomatic Influenza Transmission at Household Level by Day 511.98.6
Statistical analysis
  • Placebo: IPs vs Baloxavir Marboxil: IPs · Odds ratio (bmx vs placebo): 0.69 · 95.38% CI 0.46 to 1.04
SecondaryPercentage of HHCs With Virological Influenza Transmission by Day 9

The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 9 post IP randomization with virus subtype matching with the respective IP, irrespective of being symptomatic or asymptomatic including: 1. all HHC meeting primary endpoint, AND 2. all HHC cases detected after Day 5 meeting the following criteria: 2a. included HHC case was in an HH where another HHC had already met the primary endpoint OR 2b. included HHC case was PCR+ bearing an amino acid substitution of isoleucine for another amino acid at position 38 (I38X) in the polymerase acidic (PA) protein (PA/I38X substitution) or amino acid substitution of threonine to lysine at position 20 in the PA protein for influenza B only (PA/T20K). The adjusted incidence rates presented were estimated using a GEE approach.

Time frame:
Baseline (Day 1) to Day 9
Reported as:
Number · percentage of HHCs
Percentage of HHCs With Virological Influenza Transmission by Day 9
percentage of HHCsPlacebo: HHCsBaloxavir Marboxil: HHCs
Percentage of HHCs With Virological Influenza Transmission by Day 915.40 ± 12.2010.77 ± 8.41
Statistical analysis
  • Placebo: HHCs vs Baloxavir Marboxil: HHCs · GEE model · Adjusted or (bmx vs placebo): 0.66 · 95.38% CI 0.48 to 0.91
SecondaryPercentage of HHCs With Symptomatic Influenza Transmission by Day 9

The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who met the virological transmission by Day 9 endpoint and developed symptoms at any time during the study. The adjusted incidence rates presented were estimated using a GEE approach. HHCs ≥12 years were symptomatic if they had 1. temperature ≥38.0°C and one respiratory symptom (cough, sore throat, nasal congestion) or 2. one respiratory and one general systemic symptom (headache, feverishness or chills, muscle or joint pain, fatigue), with or without fever. HHCs ≥2 and \<12 years were symptomatic if the presence of temperature was ≥38.0°C and had upper respiratory symptoms (headache, feverishness or chills, muscle or joint pain, fatigue). Symptoms must be either new or have worsened versus baseline in HHC with baseline symptoms due to a preexisting comorbidity.

Time frame:
Baseline (Day 1) to Day 9
Reported as:
Number · percentage of HHCs
Percentage of HHCs With Symptomatic Influenza Transmission by Day 9
percentage of HHCsPlacebo: HHCsBaloxavir Marboxil: HHCs
Percentage of HHCs With Symptomatic Influenza Transmission by Day 98.26 (6.10 to 11.09)6.15 (4.37 to 8.58)
Statistical analysis
  • Placebo: HHCs vs Baloxavir Marboxil: HHCs · Two-Sided P-value · Adjusted or (bmx vs placebo): 0.73 · 95.38% CI 0.48 to 1.09
SecondaryPercentage of HHCs With Any Virological Infection by Day 9

Virological infection was defined as HHCs who tested PCR+ for influenza by Day 9 post IP randomization based on PCR influenza test results. The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who met the virological infection by Day 9 endpoint. The adjusted incidence rates presented were estimated using a GEE approach.

Time frame:
Baseline (Day 1) to Day 9
Reported as:
Number · percentage of HHCs
Percentage of HHCs With Any Virological Infection by Day 9
percentage of HHCsPlacebo: HHCsBaloxavir Marboxil: HHCs
Percentage of HHCs With Any Virological Infection by Day 918.68 ± 15.3613.98 ± 11.31
Statistical analysis
  • Placebo: HHCs vs Baloxavir Marboxil: HHCs · Two-Sided P-value · Adjusted or (bmx vs placebo): 0.71 · 95.38% CI 0.53 to 0.94
SecondaryPercentage of HHs With Any Virological Infection at HH Level by Day 9

Virological infection at the HH level was defined as the HHs with at least one HHC who met the endpoint of any virological infection by Day 9. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

Time frame:
Baseline (Day 1) to Day 9
Reported as:
Number · percentage of HHs
Percentage of HHs With Any Virological Infection at HH Level by Day 9
percentage of HHsPlacebo: IPsBaloxavir Marboxil: IPs
Percentage of HHs With Any Virological Infection at HH Level by Day 924.320.1
Statistical analysis
  • Placebo: IPs vs Baloxavir Marboxil: IPs · Odds ratio (bmx vs placebo): 0.79 · 95.38% CI 0.59 to 1.06
SecondaryPercentage of HHCs With Any Symptomatic Infection by Day 9

The adjusted incidence (cumulative proportion of events by Day 9) rate is reported here. This is defined as percentage of HHCs who tested PCR+ for influenza by Day 9 post IP randomization and developed symptoms at any time during the study. The adjusted incidence rates presented were estimated using a GEE approach. HHCs ≥12 years were symptomatic if they had (1) a temperature ≥38.0°C and one respiratory symptom (cough, sore throat, nasal congestion) or (2) one respiratory and one systemic symptom (headache, chills, muscle/joint pain, fatigue), with or without fever. HHCs ≥2 and \<12 years were symptomatic if the presence of temperature was ≥38.0°C and had upper respiratory symptoms (cough, nasal congestion, rhinorrhea). Symptoms must be either new or have worsened versus baseline in HHC with baseline symptoms due to a preexisting comorbidity.

Time frame:
Baseline (Day 1) to Day 9
Reported as:
Number · percentage of HHCs
Percentage of HHCs With Any Symptomatic Infection by Day 9
percentage of HHCsPlacebo: HHCsBaloxavir Marboxil: HHCs
Percentage of HHCs With Any Symptomatic Infection by Day 98.71 ± 6.496.43 ± 4.61
Statistical analysis
  • Placebo: HHCs vs Baloxavir Marboxil: HHCs · Two-Sided P-value · Adjusted or (bmx vs placebo): 0.72 · 95.38% CI 0.49 to 1.07
SecondaryPercentage of HHs With Any Symptomatic Infection at HH Level by Day 9

Percentage of HHs with at least one HHC who meets the endpoint of any symptomatic infection by Day 9 are reported here. HHCs ≥12 years were symptomatic if they had 1. a temperature ≥38.0°C \&1 respiratory symptom (cough, sore throat, nasal congestion) or 2. 1 respiratory \& 1 systemic symptom (headache, chills, muscle/joint pain, fatigue), with/without fever. HHCs ≥2 \& \<12 years were symptomatic if the temperature was ≥38.0°C \& had upper respiratory symptoms (cough, nasal congestion, rhinorrhea). Symptoms must be new or have worsened versus baseline in HHC with baseline symptoms due to preexisting comorbidity. 'Number of participants analyzed' is the number of IPs in the PAS-IP set.

Time frame:
Baseline (Day 1) to Day 9
Reported as:
Number · percentage of HHs
Percentage of HHs With Any Symptomatic Infection at HH Level by Day 9
percentage of HHsPlacebo: IPsBaloxavir Marboxil: IPs
Percentage of HHs With Any Symptomatic Infection at HH Level by Day 912.99.5
Statistical analysis
  • Placebo: IPs vs Baloxavir Marboxil: IPs · Odds ratio (bmx vs placebo): 0.71 · 95.38% CI 0.48 to 1.04
SecondaryNumber of IPs With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and regardless of causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product.

Time frame:
Baseline up to Day 9 (for IPs ≥12 years old) and Day 21 (for IPs <12 years old)
Reported as:
Count of participants · Participants
Number of IPs With Adverse Events (AEs)
ParticipantsPlacebo: IPsBaloxavir Marboxil: IPs
Number of IPs With Adverse Events (AEs)5133
SecondaryNumber of IPs With Serious Adverse Events (SAEs)

A SAE is any significant hazard, contraindication, side effect that is fatal or life-threatening, requires hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above.

Time frame:
Baseline up to Day 9 (for IPs ≥12 years old) and Day 21 (for IPs <12 years old)
Reported as:
Count of participants · Participants
Number of IPs With Serious Adverse Events (SAEs)
ParticipantsPlacebo: IPsBaloxavir Marboxil: IPs
Number of IPs With Serious Adverse Events (SAEs)21

Adverse events

Collected over Baseline up to Day 9 (IPs ≥12 years old) Baseline up to Day 21 (IPs <12 years old). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: IPs0/726 (0%)2/726 (0.3%)0/726 (0%)
Baloxavir Marboxil: IPs0/723 (0%)1/723 (0.1%)0/723 (0%)
Most frequent serious events
Most frequent serious events
EventPlacebo: IPsBaloxavir Marboxil: IPs
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/7261/723
BronchitisInfections and infestations1/7260/723
PneumoniaInfections and infestations1/7260/723
HyponatraemiaMetabolism and nutrition disorders1/7260/723

Baseline characteristics

Full Index Participant Analysis Set (FAS-IP) included all randomized IPs. Full Household Contact Analysis Set (FAS-HC) included all HHCs who were enrolled for the full study and linked to a randomized IP, regardless of polymerase chain reaction (PCR) test status of IP for influenza A or B. Baseline data was not collected for four participants from the 'Baloxavir Marboxil: HHCs' arm, hence data for 1341 participants is presented here.

Age, Customized
Age, Customized(Participants)Placebo: IPsBaloxavir Marboxil: IPsPlacebo: HHCsBaloxavir Marboxil: HHCsTotal
2-11 years6565152151433
12-17 years120118133124495
18-64 years5465439859893063
65-84 years006171132
≥ 85 years005611
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: IPsBaloxavir Marboxil: IPsPlacebo: HHCsBaloxavir Marboxil: HHCsTotal
Female3773897407092215
Male3543375966321919
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: IPsBaloxavir Marboxil: IPsPlacebo: HHCsBaloxavir Marboxil: HHCsTotal
Hispanic or Latino8383169153488
Not Hispanic or Latino646633113311453557
Unknown or Not Reported210344389
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: IPsBaloxavir Marboxil: IPsPlacebo: HHCsBaloxavir Marboxil: HHCsTotal
American Indian or Alaska Native779831
Asian1961903703641120
Native Hawaiian or Other Pacific Islander0010010
Black or African American28194746140
White4834958178712666
More than one race309517
Unknown or Not Reported14157447150
08

Study locations

142 sites
  • Cahaba Research, Inc.
    Birmingham, Alabama 35235, United States
  • Cahaba Research, Inc
    Pelham, Alabama 35124, United States
  • Precision Trials
    Phoenix, Arizona 85032, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • Long Beach Clinical Trials
    Long Beach, California 90806, United States
  • Downtown LA Research Center
    Los Angeles, California 90017, United States
  • Probe Clinical Research
    Riverside, California 92501, United States
  • MD Strategies Research Centers
    San Diego, California 92119, United States
  • Cherry Creek Family Practice
    Denver, Colorado 80246, United States
  • Proactive Clinical Research, LLC
    Fort Lauderdale, Florida 33308, United States
  • Helios Clinical Research, Inc (former Ventavia Research Group)
    Kissimmee, Florida 34744, United States
  • South Florida Research Center, Inc.
    Miami, Florida 33135, United States
  • Cordova Research Institute, LLC
    Miami, Florida 33155, United States
  • Research Institute of South Florida Inc
    Miami, Florida 33173, United States
  • Kendall South Medical Center Inc.
    South Miami, Florida 33185, United States
  • Agile Clinical Research Trials
    Atlanta, Georgia 30328, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Mishawaka Osteopathic Clinic
    Mishawaka, Indiana 46544, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Mercury Street Medical Group
    Butte, Montana 59701, United States
  • Montana Medical Research LLC
    Missoula, Montana 59808, United States
  • Accent Clinical Trials
    Las Vegas, Nevada 89104, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • OnSite Clinical Solutions LLC
    Charlotte, North Carolina 28277, United States
  • Burke Primary Care
    Morganton, North Carolina 28655, United States
  • Hometown Urgent Care and Occupational Health - Springdale
    Cincinnati, Ohio 45215, United States
  • Tristar Clinical Investigations
    Philadelphia, Pennsylvania 19114, United States
  • Frontier Clinical Research
    Scottdale, Pennsylvania 15683, United States
  • Frontier Clinical Research
    Smithfield, Pennsylvania 15478, United States
  • Frontier Clinical Research
    Smithfield, Pennsylvania 26505, United States
  • Jedda Enterprises dba Galen Clinical Research
    Greer, South Carolina 29651, United States
  • AFC Urgent Care-Gunbarrell
    Chattanooga, Tennessee 37421, United States
  • Helios Clinical Research, Inc (former Ventavia Research Group)
    Jackson, Tennessee 38305, United States
  • City Doc Urgent Care-Dallas/Ft. Worth
    Dallas, Texas 75204, United States
  • Southwest Family Medicine Associates
    Dallas, Texas 75235, United States
  • Premier Pulmonary Critical Care and Sleep Medicine
    Denison, Texas 75020, United States
  • Pioneer Research Solutions
    Houston, Texas 077099, United States
  • Vilo Research Group
    Houston, Texas 77017, United States
  • Fairway Medical Clinic
    Houston, Texas 77087, United States
  • Mercury Clinical Research
    Houston, Texas 77087, United States
  • Family Practice Center
    McAllen, Texas 78501, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Frontier Clinical Research
    Kingwood, West Virginia 26537, United States
  • Medical Centre "Asklepii", OOD
    Dupnitsa, 2600, Bulgaria
  • Medical Center Hera Eood
    Montana, 3400, Bulgaria
  • MHAT Sveta Paraskeva
    Pleven, 5800, Bulgaria
  • Medizinski Zentrar-1-Sevlievo EOOD
    Sevlievo, 5400, Bulgaria
  • MHAT Sliven - Military Medial Academy
    Sliven, 8800, Bulgaria
  • Medical Center Hera Sofia
    Sofia, 1510, Bulgaria
  • MHAT Sveta Sofia
    Sofia, 1618, Bulgaria
  • Capital Medical University Beijing Hospital of Traditional Chinese Medicine
    Beijing, 100010, China
  • Beijing You An Hospital
    Beijing, 100069, China
  • China-Japan Friendship Hospital
    Beijing, 10029, China
  • Beijing Tsinghua Changgung Hospital
    Beijing, 102218, China
  • West China Hospital, Sichuan University
    Chengdu, 610041, China
  • The Third People's Hospital of Hainan Province
    Sansha, 572000, China
  • Shenzhen People's Hospital
    Shenzhen, 510852, China
  • Shenzhen children's hospital
    Shenzhen, 518038, China
  • Taizhou People's Hospital
    Taizhou, 225309, China
  • The First Affiliated Hospital of Wenzhou Medical College
    Wenzhou, 325000, China
  • General Hospital of Ningxia Medical University
    Yinchuan, 750004, China
  • Henan Provincial People's Hospital
    Zhengzhou, 450003, China
  • ICIMED Instituto de Investigación en Ciencias Médicas
    San José, 10108, Costa Rica
  • Laiko General Hospital - Uni of Athens
    Athens, 115 27, Greece
  • Sotiria General Hospital of Athens
    Athens, 115 27, Greece
  • Attikon University General Hospital
    Chaïdári, 124 62, Greece
  • Obudai Egeszsegugyi Centrum Kft.
    Budapest, 1036, Hungary
  • II. Háziorvosi Körzet
    Hosszúhetény, 7694, Hungary
  • Gyermekháziorvosi rendel?- Dr. Újhelyi János
    Nyíregyháza, 4400, Hungary
  • OEC Clinical Research
    Zalaegerszeg, 8900, Hungary
  • JSS Hospital
    Mysuru, Karnataka 570004, India
  • Kiryat Motzkin Maccabi Medical Center
    Kiryat Motzkin, Israel
  • Maccabi health services - Moked Hashalom
    Tel Aviv, 6789140, Israel
  • Toda Internal Medicine & Neurology Clinic
    Akashi, 674-0081, Japan
  • Medical Corporation Houmankai?Umezu?Clinic
    Chikushino-shi, 818-0024, Japan
  • Shin Komonji Hospital
    Fukuoka, 800-0057, Japan
  • Irie Naika Syounika Iin
    Fukuoka, 812-0053, Japan
  • Kimura Siro Clinic
    Fukuoka, 819-0022, Japan
  • Iguchi Clinic
    Fukuyama, 720-0825, Japan
  • Mashiba Clinic
    Hannō, 357-0024, Japan
  • Fujimaki Ent Clinic
    Ichikawa, 272-0143, Japan
  • Hisaki Family Clinic
    Ichikawa, 272-0805, Japan
  • Moriyama Otolaryngology
    Kagoshima, 890-0034, Japan
  • Kamoike ENT Allergy Clinic
    Kagoshima, 890-0063, Japan
  • Clinic Kashiwanoha
    Kashiwa, 277-0882, Japan
  • Kamezawa Clinic
    Kasugai, 486-0817, Japan
  • Oishi Clinic
    Kasuyagun, 811-2310, Japan
  • Takahashi naika
    Kawasaki, 211-0041, Japan
  • Kanagawa Himawari Clinic
    Kawasaki, 216-0006, Japan
  • Osaki Internal and Respiratory Clinic,
    Kitakyushu, 802-0083, Japan
  • Morizono medical clinic
    Kitakyushu, 807-0072, Japan
  • Sato ENT Clinic
    Kitakyushu, 807-0856, Japan
  • Kiheibashi Otolaryngology
    Kodaira, 187-0044, Japan
  • Medical corporation Shirayurikai Swing Nozaki Clinic
    Musashino, 180-0022, Japan
  • Yaesu Clinic
    Naha, 900-0032, Japan
  • Horikawa Clinic
    Nonoichi, 921-8801, Japan
  • Lee's Clinic
    Osaka, 531-0073, Japan
  • Kitada Clinic
    Osaka, 538-0044, Japan
  • Sunami Internal medicine Clinic
    Osaka, 538-0044, Japan
  • Funai Ear Nose Throat Clinic
    Ōita, 870-0021, Japan

Showing the first 100 of 142 sites across 16 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Monto AS, Kuhlbusch K, Bernasconi C, Cao B, Cohen HA, Graham E, Hurt AC, Katugampola L, Kamezawa T, Lauring AS, McLean B, Takazono T, Widmer A, Wildum S, Cowling BJ. Efficacy of Baloxavir Treatment in Preventing Transmission of Influenza. N Engl J Med. 2025 Apr 24;392(16):1582-1593. doi: 10.1056/NEJMoa2413156. PubMed 40267424 ↗
  • Komeda T, Takazono T, Hosogaya N, Ogura E, Fujiwara M, Miyauchi H, Ajisawa Y, Iwata S, Watanabe H, Honda K, Kitanishi Y, Hara K, Mukae H. Comparison of Household Transmission of Influenza Virus From Index Patients Treated With Baloxavir Marboxil or Neuraminidase Inhibitors: A Health Insurance Claims Database Study. Clin Infect Dis. 2021 Jun 1;72(11):e859-e867. doi: 10.1093/cid/ciaa1622. PubMed 33103200 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in May 2024, 55 months.

Results were first posted in Apr 2025, 11 months after primary completion.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 55 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2019
First posted
May 31, 2019
StartActual
Oct 10, 2019
Primary completionActual
May 10, 2024
CompletionActual
May 10, 2024
Results first posted
Apr 24, 2025
Last update
Jul 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03969212
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 31, 2019
Start date
Oct 10, 2019
Primary completion
May 10, 2024
Completion
May 10, 2024
Results posted
Apr 24, 2025
Last update
Jul 4, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion